Drug name - Lybalvi

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7262298 ALKERMES INC 4-hydroxybenzomorphans
Nov, 2025

(2 years from now)

US9119848 ALKERMES INC Morphinan derivatives for the treatment of drug overdose
Aug, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11185541 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US9126977 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US9517235 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US10716785 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US10300054 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US11351166 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US11241425 ALKERMES INC Composition for treating mental illness
Aug, 2031

(8 years from now)

US8778960 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Feb, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

Market Authorisation Date: 28 May, 2021

Treatment: Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduction of the adverse metabolic profile; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduction of the adverse metabolic profile; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;EQ 10MG BASE TABLET;ORAL Prescription
10MG;EQ 10MG BASE TABLET;ORAL Prescription
15MG;EQ 10MG BASE TABLET;ORAL Prescription
20MG;EQ 10MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.